Drug · DIN 02230845
FLOLAN
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since February 25, 2003; first marketed July 28, 1997.
- Drug Identification Number (DIN)
- 02230845
- Company (DIN owner)
- Glaxosmithkline IncMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Epoprostenol B01AC09
- Class
- Human
- Record last updated
- June 24, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| EPOPROSTENOL (EPOPROSTENOL SODIUM) | 0.5 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 7, 2001: NOC 2221New Drug Submission (NDS) · Change in manufacturer name
- March 6, 1997: NOC 3767New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “flolan”. A notice may cover another product or only some lots: read it to see what it covers.
- Flolan (2015-03-20)March 24, 2015 · Drugs · Product safety · Type II
- FLOLAN (epoprostenol sodium) - Potential for Glass-related Particles in Sterile Diluent - For the PublicApril 24, 2013 · Drugs · Contamination
- FLOLAN (epoprostenol sodium) - Potential for Glass-related Particles in Sterile Diluent - For Healthcare ProfessionalsApril 24, 2013 · Drugs · Contamination
Other DINs named FLOLAN
- DIN 02230848 · Marketed